Completed

MARVEL2Micra Atrial TRacking Using A Ventricular AccELerometer 2

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

MARVEL 2 Algorithm Monitor Mode then Adaptive Mode

Device
Who is being recruted

Cardiac Conduction System Disease+5

+ Arrhythmias, Cardiac

+ Cardiovascular Diseases

Over 18 Years
+8 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: January 2019
See protocol details

Summary

Principal SponsorMedtronic Cardiac Rhythm and Heart Failure
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 22, 2019

Actual date on which the first participant was enrolled.

The MARVEL 2 study is an acute, prospective, global, multi-center, software-download clinical study. The study is planned to be conducted in US, Europe, and Asia. The study is expected to be conducted at approximately 15-20 centers in up to 100 subjects to obtain at least 70 usable Holter datasets to meet the objectives of the study. The expected total study duration (from first subject enrollment to the exit of the last subject) is approximately 6-months; this represents the time necessary to enroll the target sample size of at least 70 subjects with usable Holter datasets. Software will be downloaded into patients implanted with a Micra device to allow the new algorithm performance to be measured in patients where a Micra device has already been chosen as most appropriate for the patient. Most enrolled subjects will complete the study procedures during a single study visit. However, subjects enrolling in the study at the time of their Micra implant (anticipated to be approximately 10 subjects) will have the investigational algorithm downloaded following Micra implant, prior to hospital discharge, and approximately 1-month post-implant. This subset of subjects with de novo Micra implants will allow the MARVEL 2 features to be tested at multiple points in the device life cycle. Since the download algorithm running in a Micra device significantly increases current drain, a 2-4 hour acute study is used to limit the reduction in device longevity.

Official TitleMicra Atrial TRacking Using A Ventricular AccELerometer 2
NCT03752151
Principal SponsorMedtronic Cardiac Rhythm and Heart Failure
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

77 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiac Conduction System DiseaseArrhythmias, CardiacCardiovascular DiseasesHeart BlockHeart DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsAtrioventricular Block

Criteria

5 inclusion criteria required to participate
Subject has been implanted with a Micra TPS (Model MC1VR01) with remaining device longevity of 6 years or more or is expected to be implanted with a Micra TPS.

Subject has history of AV block*

Subject is ≥ 18 years old and as per required local law.

Subject (and/or witness as applicable per local regulations) provides signed and dated authorization and/or consent per institution and local requirements.

Show More Criteria

3 exclusion criteria prevent from participating
Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic Clinical Research Specialist.

Subject is pregnant (if required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to MARVEL 2 study procedures).

Subject meets any exclusion criteria required by local law (age or other).

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Participants first received MARVEL 2 algorithm monitor mode which provides standard VVI pacing for approximately 20 minutes followed by MARVEL 2 algorithm adaptive mode for approximately 2 hours which provides VDD pacing.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 12 locations

Suspended

Baptist Medical Center Jacksonville

Jacksonville, United StatesOpen Baptist Medical Center Jacksonville in Google Maps
Suspended

Baptist Hospital

Miami, United States
Suspended

North Shore University Hospital- Northwell

Manhasset, United States
Suspended

NYU Langone Medical Center

New York, United States
Completed12 Study Centers